You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTorasemide
Accession NumberDB00214  (APRD00295, APRD00217)
TypeSmall Molecule
GroupsApproved
DescriptionTorasemide (rINN) or torsemide (USAN) is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. [Wikipedia]
Structure
Thumb
Synonyms
1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
Demadex
Luprac
N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
Torasemida
Torasemidum
Torsemide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Demadextablet20 mg/1oralPhysicians Total Care, Inc.2009-10-21Not applicableUs
Demadextablet5 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs
Demadextablet10 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us
Demadextablet100 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs
Demadextablet10 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs
Demadextablet20 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us
Demadextablet20 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs
Demadextablet100 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us
Demadextablet10 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs
Demadextablet5 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us
Demadex Injection - 10mg/mlliquid10 mgintravenousHoffmann La Roche Limited1995-12-312000-07-27Canada
Demadex Tablets - 100mgtablet100 mgoralHoffmann La Roche Limited1995-12-312000-07-27Canada
Demadex Tablets - 10mgtablet10 mgoralHoffmann La Roche Limited1995-12-312000-07-27Canada
Demadex Tablets - 20mgtablet20 mgoralHoffmann La Roche Limited1996-12-312000-07-27Canada
Demadex Tablets - 5mgtablet5 mgoralHoffmann La Roche Limited1995-12-312000-07-27Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Torsemidetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-07-19Not applicableUs
Torsemidetablet10 mg/1oralAv Pak2014-10-07Not applicableUs
Torsemidetablet100 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs
Torsemidetablet20 mg/1oralAmerican Health Packaging2013-07-22Not applicableUs
Torsemidetablet20 mg/1oralRoxane Laboratories, Inc2005-03-03Not applicableUs
Torsemidetablet20 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs
Torsemidetablet20 mg/1oralCardinal Health2010-01-14Not applicableUs
Torsemidetablet100 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs
Torsemidetablet100 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Torsemideinjection10 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2010-06-01Not applicableUs
Torsemidetablet100 mg/1oralApotex Corp.2005-06-06Not applicableUs
Torsemidetablet10 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs
Torsemidetablet10 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs
Torsemidetablet20 mg/1oralPliva, Inc2004-06-01Not applicableUs
Torsemidetablet5 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs
Torsemidetablet5 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Torsemidetablet20 mg/1oralAv Pak2014-10-07Not applicableUs
Torsemidetablet5 mg/1oralApotex Corp.2005-06-06Not applicableUs
Torsemidetablet5 mg/1oralCarilion Materials Management2011-01-01Not applicableUs
Torsemideinjection, solution10 mg/mLintravenousAmerican Regent, Inc.2010-05-21Not applicableUs
Torsemidetablet100 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs
Torsemidetablet10 mg/1oralCardinal Health2010-01-14Not applicableUs
Torsemidetablet10 mg/1oralbryant ranch prepack2011-01-01Not applicableUs
Torsemidetablet5 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs
Torsemidetablet100 mg/1oralAv Kare, Inc.2014-12-29Not applicableUs
Torsemidetablet100 mg/1oralPhysicians Total Care, Inc.2012-08-17Not applicableUs
Torsemidetablet100 mg/1oralPliva, Inc2004-10-20Not applicableUs
Torsemidetablet10 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs
Torsemidetablet20 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs
Torsemidetablet20 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs
Torsemidetablet10 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Torsemidetablet100 mg/1oralAv Pak2014-10-07Not applicableUs
Torsemidetablet10 mg/1oralApotex Corp.2005-06-06Not applicableUs
Torsemidetablet100 mg/1oralCarilion Materials Management2011-01-01Not applicableUs
Torsemideinjection, solution10 mg/mLintravenousAmerican Regent, Inc.2010-05-26Not applicableUs
Torsemidetablet5 mg/1oralPliva, Inc2004-06-01Not applicableUs
Torsemidetablet20 mg/1oralCardinal Health2004-06-01Not applicableUs
Torsemidetablet20 mg/1oralbryant ranch prepack2009-01-27Not applicableUs
Torsemidetablet5 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs
Torsemidetablet20 mg/1oralPhysicians Total Care, Inc.2005-04-01Not applicableUs
Torsemidetablet10 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs
Torsemidetablet100 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs
Torsemidetablet5 mg/1oralAv Pak2014-10-07Not applicableUs
Torsemidetablet20 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs
Torsemidetablet100 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs
Torsemidetablet20 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Torsemideinjection10 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2010-06-01Not applicableUs
Torsemidetablet20 mg/1oralApotex Corp.2005-06-06Not applicableUs
Torsemidetablet20 mg/1oralCarilion Materials Management2011-01-01Not applicableUs
Torsemidetablet5 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs
Torsemidetablet10 mg/1oralPliva, Inc2004-06-01Not applicableUs
Torsemidetablet10 mg/1oralCardinal Health2004-06-01Not applicableUs
Torsemidetablet5 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs
Torsemidetablet10 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs
Torsemidetablet10 mg/1oralPhysicians Total Care, Inc.2009-06-26Not applicableUs
Torsemidetablet20 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiuverNot Available
ExamideNot Available
LupracNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIW31X2H97FB
CAS number56211-40-6
WeightAverage: 348.42
Monoisotopic: 348.125611216
Chemical FormulaC16H20N4O3S
InChI KeyInChIKey=NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
IUPAC Name
1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinesulfonamides
Direct ParentPyridinesulfonamides
Alternative Parents
Substituents
  • Pyridine-3-sulfonamide
  • Aminotoluene
  • Substituted aniline
  • Toluene
  • Sulfonylurea
  • Aniline
  • Aminopyridine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
PharmacodynamicsTorasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorption is accomplished by a Na+/K+/2Cl- symporter. The thick ascending limb has a high reabsorptive capacity and is responsible for reabsorbing 25% of the filtered load of Na+. The loop diuretics act by blocking this symporter. Because of the large absorptive capacity and the amount of Na+ delivered to the ascending limb, loop diuretics have a profound diuretic action. In addition, more distal nephron segments do not have the reabsorptive capacity to compensate for this increased load. The osmotic gradient for water reabsorption is also reduced resulting in an increase in the amount of water excreted.
Mechanism of actionTorasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and By increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.
Related Articles
AbsorptionRapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption.
Volume of distribution
  • 12 to 15 L [normal adults or in patients with mild to moderate renal failure or congestive heart failure]
Protein binding> 99%
Metabolism

Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.

SubstrateEnzymesProduct
Torasemide
hydroxytorsemideDetails
Route of eliminationTorsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function).
Half life3.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Torsemide Action PathwayDrug actionSMP00118
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.6871
Caco-2 permeable-0.5374
P-glycoprotein substrateNon-substrate0.799
P-glycoprotein inhibitor INon-inhibitor0.7695
P-glycoprotein inhibitor IINon-inhibitor0.8232
Renal organic cation transporterNon-inhibitor0.9185
CYP450 2C9 substrateSubstrate0.6049
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6692
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6324
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8366
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8740 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9854
hERG inhibition (predictor II)Non-inhibitor0.8668
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Bedford laboratories
  • Luitpold pharmaceuticals inc
  • Meda pharmaceuticals inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Hetero drugs ltd
  • Par pharmaceutical inc
  • Pliva pharmaceutical industry inc
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral100 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Liquidintravenous10 mg
Tabletoral100 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral5 mg
Injectionintravenous10 mg/mL
Injection, solutionintravenous10 mg/mL
Prices
Unit descriptionCostUnit
Demadex 100 mg tablet5.69USD tablet
Torsemide 100 mg tablet3.16USD tablet
Demadex 20 mg tablet1.59USD tablet
Demadex 10 mg tablet1.39USD tablet
Demadex 5 mg tablet1.28USD tablet
Torsemide 20 mg tablet0.85USD tablet
Torsemide 10 mg tablet0.73USD tablet
Torsemide 5 mg tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point164-164 °CNot Available
water solubilityWater solubleNot Available
logP2.3Not Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0596 mg/mLALOGPS
logP1.76ALOGPS
logP1.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.89 m3·mol-1ChemAxon
Polarizability36.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Fritz Topfmeier, Gustav Lettenbauer, “Process for the preparation of a stable modification of torasemide.” U.S. Patent USRE0345806, issued June, 1975.

USRE0345806
General References
  1. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212 ]
  2. Authors unspecified: FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. [PubMed:8197389 ]
External Links
ATC CodesC03CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (110 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Torasemide.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Torasemide.
AbirateroneThe serum concentration of Torasemide can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Torasemide.
AcebutololTorasemide may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the diuretic activities of Torasemide.
AcetazolamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Torasemide.
AdapaleneAdapalene may decrease the diuretic activities of Torasemide.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Torasemide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Torasemide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.
AldosteroneAldosterone may increase the hypokalemic activities of Torasemide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Torasemide.
AliskirenTorasemide may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk or severity of adverse effects can be increased when Torasemide is combined with Allopurinol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Torasemide.
AlprenololTorasemide may increase the hypotensive activities of Alprenolol.
AmbrisentanTorasemide may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Torasemide.
AmifostineTorasemide may increase the hypotensive activities of Amifostine.
AmikacinThe risk or severity of adverse effects can be increased when Torasemide is combined with Amikacin.
AmilorideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amiloride.
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Torasemide.
AmiodaroneThe metabolism of Torasemide can be decreased when combined with Amiodarone.
AmlodipineTorasemide may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Torasemide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Torasemide is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the diuretic activities of Torasemide.
ApraclonidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Apraclonidine.
ApremilastApremilast may decrease the diuretic activities of Torasemide.
AprepitantThe metabolism of Torasemide can be increased when combined with Aprepitant.
ArbutamineArbutamine may increase the hypokalemic activities of Torasemide.
ArformoterolArformoterol may increase the hypokalemic activities of Torasemide.
AripiprazoleAripiprazole may increase the hypotensive activities of Torasemide.
AtenololTorasemide may increase the hypotensive activities of Atenolol.
AzapropazoneAzapropazone may decrease the diuretic activities of Torasemide.
AzelastineAzelastine may decrease the diuretic activities of Torasemide.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the diuretic activities of Torasemide.
BambuterolBambuterol may increase the hypokalemic activities of Torasemide.
BarbitalBarbital may increase the hypotensive activities of Torasemide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Torasemide.
BenazeprilTorasemide may increase the hypotensive activities of Benazepril.
BendroflumethiazideTorasemide may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Torasemide.
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Torasemide.
BepridilTorasemide may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Torasemide.
BetaxololBetaxolol may increase the hypotensive activities of Torasemide.
BethanidineTorasemide may increase the hypotensive activities of Bethanidine.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Torasemide.
BimatoprostTorasemide may increase the hypotensive activities of Bimatoprost.
BisoprololTorasemide may increase the hypotensive activities of Bisoprolol.
BosentanTorasemide may increase the hypotensive activities of Bosentan.
BretyliumTorasemide may increase the hypotensive activities of Bretylium.
BrimonidineTorasemide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Torasemide.
BromfenacBromfenac may decrease the diuretic activities of Torasemide.
BudesonideBudesonide may increase the hypokalemic activities of Torasemide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Torasemide.
BumetanideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.
BupranololTorasemide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Torasemide.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Torasemide.
CandesartanTorasemide may increase the hypotensive activities of Candesartan.
CandoxatrilTorasemide may increase the hypotensive activities of Candoxatril.
CapecitabineThe metabolism of Torasemide can be decreased when combined with Capecitabine.
CaptoprilTorasemide may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Torasemide can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Torasemide.
CaroxazoneCaroxazone may increase the hypotensive activities of Torasemide.
CarprofenCarprofen may decrease the diuretic activities of Torasemide.
CarteololTorasemide may increase the hypotensive activities of Carteolol.
CarvedilolTorasemide may increase the hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the diuretic activities of Torasemide.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Torasemide.
CelecoxibThe metabolism of Torasemide can be decreased when combined with Celecoxib.
CeliprololTorasemide may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Torasemide can be increased when it is combined with Ceritinib.
ChloroquineChloroquine may decrease the diuretic activities of Torasemide.
ChlorothiazideTorasemide may increase the hypotensive activities of Chlorothiazide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.
ChlorthalidoneTorasemide may increase the hypotensive activities of Chlorthalidone.
CholecalciferolThe metabolism of Torasemide can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Torasemide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Torasemide.
CilazaprilTorasemide may increase the hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Torasemide.
CisplatinTorasemide may increase the nephrotoxic activities of Cisplatin.
ClenbuterolClenbuterol may increase the hypokalemic activities of Torasemide.
ClevidipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Torasemide.
ClocortoloneClocortolone may increase the hypokalemic activities of Torasemide.
ClonidineTorasemide may increase the hypotensive activities of Clonidine.
ClonixinClonixin may decrease the diuretic activities of Torasemide.
ClopidogrelThe metabolism of Torasemide can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Torasemide can be decreased when combined with Clotrimazole.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Torasemide.
ColesevelamColesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Torasemide.
CryptenamineTorasemide may increase the hypotensive activities of Cryptenamine.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.
CyclothiazideTorasemide may increase the hypotensive activities of Cyclothiazide.
D-LimoneneD-Limonene may decrease the diuretic activities of Torasemide.
DabrafenibThe serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.
DapagliflozinThe risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin.
DaunorubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Daunorubicin.
DebrisoquinTorasemide may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Torasemide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Torasemide.
DelavirdineThe metabolism of Torasemide can be decreased when combined with Delavirdine.
DeserpidineTorasemide may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Torasemide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Torasemide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Torasemide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Torasemide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Torasemide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Torasemide.
DiazoxideDiazoxide may increase the hypotensive activities of Torasemide.
DiclofenacDiclofenac may decrease the diuretic activities of Torasemide.
DiclofenamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Diclofenamide.
DiflorasoneDiflorasone may increase the hypokalemic activities of Torasemide.
DiflunisalDiflunisal may decrease the diuretic activities of Torasemide.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Torasemide.
DifluprednateDifluprednate may increase the hypokalemic activities of Torasemide.
DigitoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Dihydrostreptomycin.
DiltiazemTorasemide may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide.
DipivefrinDipivefrin may increase the hypokalemic activities of Torasemide.
DipyridamoleThe risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Torasemide.
DofetilideTorasemide may increase the QTc-prolonging activities of Dofetilide.
DorzolamideTorasemide may increase the hypotensive activities of Dorzolamide.
DoxazosinTorasemide may increase the hypotensive activities of Doxazosin.
DoxorubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Doxorubicin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Torasemide.
DroxicamDroxicam may decrease the diuretic activities of Torasemide.
DroxidopaDroxidopa may increase the hypokalemic activities of Torasemide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Torasemide.
DuloxetineTorasemide may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe metabolism of Torasemide can be decreased when combined with Efavirenz.
EfonidipineTorasemide may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Torasemide.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Torasemide.
EnalaprilTorasemide may increase the hypotensive activities of Enalapril.
EnalaprilatTorasemide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Torasemide.
EpinephrineEpinephrine may increase the hypokalemic activities of Torasemide.
EpirizoleEpirizole may decrease the diuretic activities of Torasemide.
EpirubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Epirubicin.
EplerenoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Eplerenone.
EpoprostenolTorasemide may increase the hypotensive activities of Epoprostenol.
EprosartanTorasemide may increase the hypotensive activities of Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Torasemide.
EquilinEquilin may increase the hypokalemic activities of Torasemide.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide.
EstroneEstrone may increase the hypokalemic activities of Torasemide.
Etacrynic acidThe risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the diuretic activities of Torasemide.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide.
EtodolacEtodolac may decrease the diuretic activities of Torasemide.
EtofenamateEtofenamate may decrease the diuretic activities of Torasemide.
EtoricoxibEtoricoxib may decrease the diuretic activities of Torasemide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide.
EtravirineThe metabolism of Torasemide can be decreased when combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Torasemide.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Torasemide.
exisulindexisulind may decrease the diuretic activities of Torasemide.
FelodipineTorasemide may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the diuretic activities of Torasemide.
FenoldopamTorasemide may increase the hypotensive activities of Fenoldopam.
FenoprofenFenoprofen may decrease the diuretic activities of Torasemide.
FenoterolFenoterol may increase the hypokalemic activities of Torasemide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.
FloctafenineFloctafenine may decrease the diuretic activities of Torasemide.
FloxuridineThe metabolism of Torasemide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Torasemide can be decreased when combined with Fluconazole.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Torasemide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Torasemide.
FlunisolideFlunisolide may increase the hypokalemic activities of Torasemide.
FlunixinFlunixin may decrease the diuretic activities of Torasemide.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Torasemide.
FluocinonideFluocinonide may increase the hypokalemic activities of Torasemide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Torasemide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Torasemide.
FluorouracilThe metabolism of Torasemide can be decreased when combined with Fluorouracil.
FluprednideneFluprednidene may increase the hypokalemic activities of Torasemide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Torasemide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Torasemide.
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Torasemide.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Torasemide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Torasemide.
FluvastatinThe metabolism of Torasemide can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Torasemide can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the hypokalemic activities of Torasemide.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Torasemide.
FosinoprilTorasemide may increase the hypotensive activities of Fosinopril.
FosphenytoinFosphenytoin may decrease the diuretic activities of Torasemide.
FramycetinThe risk or severity of adverse effects can be increased when Torasemide is combined with Framycetin.
FurazolidoneFurazolidone may increase the hypotensive activities of Torasemide.
FurosemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.
GemfibrozilThe metabolism of Torasemide can be decreased when combined with Gemfibrozil.
GentamicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Gentamicin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Torasemide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Torasemide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Torasemide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Torasemide.
GuanabenzTorasemide may increase the hypotensive activities of Guanabenz.
GuanadrelTorasemide may increase the hypotensive activities of Guanadrel.
GuanethidineTorasemide may increase the hypotensive activities of Guanethidine.
GuanfacineTorasemide may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Torasemide.
HexamethoniumTorasemide may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Torasemide.
HMPL-004HMPL-004 may decrease the diuretic activities of Torasemide.
HydracarbazineHydracarbazine may increase the hypotensive activities of Torasemide.
HydralazineTorasemide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideTorasemide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Torasemide.
HydroflumethiazideTorasemide may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.
Hygromycin BThe risk or severity of adverse effects can be increased when Torasemide is combined with Hygromycin B.
IbuprofenIbuprofen may decrease the diuretic activities of Torasemide.
IbuproxamIbuproxam may decrease the diuretic activities of Torasemide.
IcatibantIcatibant may decrease the diuretic activities of Torasemide.
IdarubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Idarubicin.
IloprostIloprost may increase the hypotensive activities of Torasemide.
IndacaterolIndacaterol may increase the hypokalemic activities of Torasemide.
IndapamideTorasemide may increase the hypotensive activities of Indapamide.
IndenololTorasemide may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Torasemide can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the diuretic activities of Torasemide.
IndoprofenIndoprofen may decrease the diuretic activities of Torasemide.
IndoraminTorasemide may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Torasemide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Torasemide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide.
IproclozideIproclozide may increase the hypotensive activities of Torasemide.
IproniazidIproniazid may increase the hypotensive activities of Torasemide.
IrbesartanTorasemide may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Torasemide.
IsoetarineIsoetarine may increase the hypokalemic activities of Torasemide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Torasemide.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the diuretic activities of Torasemide.
IsoxsuprineThe risk or severity of adverse effects can be increased when Torasemide is combined with Isoxsuprine.
IsradipineTorasemide may increase the hypotensive activities of Isradipine.
IvabradineTorasemide may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Kanamycin.
KebuzoneKebuzone may decrease the diuretic activities of Torasemide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide.
KetoconazoleThe metabolism of Torasemide can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the diuretic activities of Torasemide.
KetorolacKetorolac may decrease the diuretic activities of Torasemide.
LabetalolTorasemide may increase the hypotensive activities of Labetalol.
LacidipineTorasemide may increase the hypotensive activities of Lacidipine.
LapatinibThe metabolism of Torasemide can be decreased when combined with Lapatinib.
LatanoprostTorasemide may increase the hypotensive activities of Latanoprost.
LeflunomideThe metabolism of Torasemide can be decreased when combined with Leflunomide.
LercanidipineTorasemide may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Torasemide is combined with Levobunolol.
LevodopaTorasemide may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.
LicoriceLicorice may increase the hypokalemic activities of Torasemide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Torasemide.
LisinoprilTorasemide may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Torasemide.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Torasemide.
LofexidineTorasemide may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Torasemide can be decreased when combined with Lopinavir.
LornoxicamLornoxicam may decrease the diuretic activities of Torasemide.
LosartanTorasemide may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Torasemide can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the diuretic activities of Torasemide.
LumacaftorThe serum concentration of Torasemide can be decreased when it is combined with Lumacaftor.
LumiracoxibLumiracoxib may decrease the diuretic activities of Torasemide.
MacitentanTorasemide may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Torasemide.
ManidipineTorasemide may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.
MasoprocolMasoprocol may decrease the diuretic activities of Torasemide.
MebanazineMebanazine may increase the hypotensive activities of Torasemide.
MecamylamineTorasemide may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Torasemide.
MedrysoneMedrysone may increase the hypokalemic activities of Torasemide.
Mefenamic acidMefenamic acid may decrease the diuretic activities of Torasemide.
MelengestrolMelengestrol may increase the hypokalemic activities of Torasemide.
MeloxicamMeloxicam may decrease the diuretic activities of Torasemide.
MesalazineMesalazine may decrease the diuretic activities of Torasemide.
MetamizoleMetamizole may decrease the diuretic activities of Torasemide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Torasemide.
MethazolamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Torasemide.
MethotrexateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.
MethyldopaTorasemide may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Torasemide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Torasemide.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Torasemide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Torasemide.
MetipranololTorasemide may increase the hypotensive activities of Metipranolol.
MetolazoneTorasemide may increase the hypotensive activities of Metolazone.
MetoprololTorasemide may increase the hypotensive activities of Metoprolol.
MetrizamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metrizamide.
MibefradilTorasemide may increase the hypotensive activities of Mibefradil.
MifepristoneThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Torasemide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Torasemide.
MinaprineMinaprine may increase the hypotensive activities of Torasemide.
MinoxidilTorasemide may increase the hypotensive activities of Minoxidil.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Torasemide.
MoclobemideMoclobemide may increase the hypotensive activities of Torasemide.
MoexiprilTorasemide may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Torasemide.
MometasoneMometasone may increase the hypokalemic activities of Torasemide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.
MoxonidineTorasemide may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Torasemide.
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Torasemide.
NabumetoneNabumetone may decrease the diuretic activities of Torasemide.
NadololTorasemide may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the diuretic activities of Torasemide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.
NaproxenNaproxen may decrease the diuretic activities of Torasemide.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Torasemide.
NCX 4016NCX 4016 may decrease the diuretic activities of Torasemide.
NebivololTorasemide may increase the hypotensive activities of Nebivolol.
NeomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Neomycin.
NepafenacNepafenac may decrease the diuretic activities of Torasemide.
NesiritideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nesiritide.
NetilmicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Netilmicin.
NialamideNialamide may increase the hypotensive activities of Torasemide.
NicardipineTorasemide may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Torasemide.
NifedipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Torasemide.
NiguldipineTorasemide may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Torasemide can be decreased when combined with Nilotinib.
NilvadipineTorasemide may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the diuretic activities of Torasemide.
NimodipineTorasemide may increase the hypotensive activities of Nimodipine.
NisoldipineTorasemide may increase the hypotensive activities of Nisoldipine.
NitrendipineTorasemide may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroglycerin.
NitroprussideTorasemide may increase the hypotensive activities of Nitroprusside.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Torasemide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Torasemide.
ObinutuzumabTorasemide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Torasemide.
OlmesartanTorasemide may increase the hypotensive activities of Olmesartan.
OlodaterolOlodaterol may increase the hypokalemic activities of Torasemide.
OlopatadineOlopatadine may decrease the diuretic activities of Torasemide.
OlsalazineOlsalazine may decrease the diuretic activities of Torasemide.
OmapatrilatTorasemide may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe metabolism of Torasemide can be decreased when combined with Omeprazole.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Torasemide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Torasemide.
OrgoteinOrgotein may decrease the diuretic activities of Torasemide.
OuabainThe risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain.
OxaprozinOxaprozin may decrease the diuretic activities of Torasemide.
OxprenololTorasemide may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide.
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Torasemide.
PapaverineThe risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Torasemide.
ParecoxibParecoxib may decrease the diuretic activities of Torasemide.
PargylineTorasemide may increase the hypotensive activities of Pargyline.
ParomomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Paromomycin.
PenbutololTorasemide may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.
PentobarbitalPentobarbital may increase the hypotensive activities of Torasemide.
PentoliniumTorasemide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Torasemide.
PerindoprilTorasemide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.
PhenelzinePhenelzine may increase the hypotensive activities of Torasemide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Torasemide.
PheniprazinePheniprazine may increase the hypotensive activities of Torasemide.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Torasemide.
PhenoxybenzamineTorasemide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Torasemide.
PhentolamineTorasemide may increase the hypotensive activities of Phentolamine.
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Torasemide.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Torasemide.
PhenytoinPhenytoin may decrease the diuretic activities of Torasemide.
PimecrolimusPimecrolimus may decrease the diuretic activities of Torasemide.
PinacidilTorasemide may increase the hypotensive activities of Pinacidil.
PindololTorasemide may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Torasemide.
PioglitazoneThe metabolism of Torasemide can be decreased when combined with Pioglitazone.
PirbuterolPirbuterol may increase the hypokalemic activities of Torasemide.
PirfenidonePirfenidone may decrease the diuretic activities of Torasemide.
PirlindolePirlindole may increase the hypotensive activities of Torasemide.
PiroxicamPiroxicam may decrease the diuretic activities of Torasemide.
PivhydrazinePivhydrazine may increase the hypotensive activities of Torasemide.
PlicamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Plicamycin.
PolythiazideTorasemide may increase the hypotensive activities of Polythiazide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Torasemide.
PrazosinTorasemide may increase the hypotensive activities of Prazosin.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Torasemide.
PrednisolonePrednisolone may increase the hypokalemic activities of Torasemide.
PrednisonePrednisone may increase the hypokalemic activities of Torasemide.
PregnenolonePregnenolone may increase the hypokalemic activities of Torasemide.
PrimidonePrimidone may increase the hypotensive activities of Torasemide.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide.
ProcaterolProcaterol may increase the hypokalemic activities of Torasemide.
PropacetamolPropacetamol may decrease the diuretic activities of Torasemide.
PropranololTorasemide may increase the hypotensive activities of Propranolol.
PTC299PTC299 may decrease the diuretic activities of Torasemide.
PuromycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Puromycin.
PyrimethamineThe metabolism of Torasemide can be decreased when combined with Pyrimethamine.
QuetiapineThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.
QuinaprilTorasemide may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Torasemide.
RabeprazoleThe metabolism of Torasemide can be decreased when combined with Rabeprazole.
RamiprilRamipril may increase the hypotensive activities of Torasemide.
RasagilineRasagiline may increase the hypotensive activities of Torasemide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.
RemikirenRemikiren may increase the hypotensive activities of Torasemide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide.
RescinnamineTorasemide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Torasemide.
ResveratrolResveratrol may decrease the diuretic activities of Torasemide.
RibostamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.
RifampicinThe metabolism of Torasemide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Torasemide can be increased when combined with Rifapentine.
RimexoloneRimexolone may increase the hypokalemic activities of Torasemide.
RiociguatTorasemide may increase the hypotensive activities of Riociguat.
RisperidoneTorasemide may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Torasemide.
RitonavirThe metabolism of Torasemide can be decreased when combined with Ritonavir.
RituximabTorasemide may increase the hypotensive activities of Rituximab.
RofecoxibRofecoxib may decrease the diuretic activities of Torasemide.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Torasemide.
RosiglitazoneThe metabolism of Torasemide can be decreased when combined with Rosiglitazone.
SafrazineSafrazine may increase the hypotensive activities of Torasemide.
SalbutamolSalbutamol may increase the hypokalemic activities of Torasemide.
SalicylamideSalicylamide may decrease the diuretic activities of Torasemide.
Salicylic acidSalicylic acid may decrease the diuretic activities of Torasemide.
SalmeterolSalmeterol may increase the hypokalemic activities of Torasemide.
SalsalateSalsalate may decrease the diuretic activities of Torasemide.
SaprisartanTorasemide may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Torasemide.
SecobarbitalSecobarbital may increase the hypotensive activities of Torasemide.
SelegilineSelegiline may increase the hypotensive activities of Torasemide.
SelexipagTorasemide may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the diuretic activities of Torasemide.
SildenafilSildenafil may increase the antihypertensive activities of Torasemide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Torasemide.
SitaxentanTorasemide may increase the hypotensive activities of Sitaxentan.
SorafenibThe metabolism of Torasemide can be decreased when combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.
SpectinomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Spectinomycin.
SpiraprilTorasemide may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone.
SRT501SRT501 may decrease the diuretic activities of Torasemide.
StiripentolThe metabolism of Torasemide can be decreased when combined with Stiripentol.
StreptomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptomycin.
StreptozocinThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.
SulfadiazineThe metabolism of Torasemide can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfamethoxazole.
SulfasalazineSulfasalazine may decrease the diuretic activities of Torasemide.
SulfisoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the diuretic activities of Torasemide.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide.
SulpirideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.
SuprofenSuprofen may decrease the diuretic activities of Torasemide.
TadalafilTadalafil may increase the antihypertensive activities of Torasemide.
TamoxifenThe metabolism of Torasemide can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide.
TelmisartanTorasemide may increase the hypotensive activities of Telmisartan.
TemocaprilTorasemide may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the diuretic activities of Torasemide.
TepoxalinTepoxalin may decrease the diuretic activities of Torasemide.
TerazosinThe risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Torasemide.
TeriflunomideThe metabolism of Torasemide can be decreased when combined with Teriflunomide.
TerlipressinTorasemide may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Torasemide.
ThiopentalThiopental may increase the hypotensive activities of Torasemide.
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Torasemide.
TiboloneTorasemide may increase the hypotensive activities of Tibolone.
TicagrelorThe metabolism of Torasemide can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Torasemide can be decreased when combined with Ticlopidine.
TicrynafenTorasemide may increase the hypotensive activities of Ticrynafen.
TimololTorasemide may increase the hypotensive activities of Timolol.
TixocortolTixocortol may increase the hypokalemic activities of Torasemide.
TizanidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.
TobramycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Tobramycin.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide.
TolazolineTorasemide may increase the hypotensive activities of Tolazoline.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Torasemide.
TolbutamideThe metabolism of Torasemide can be decreased when combined with Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Torasemide.
TolmetinTolmetin may decrease the diuretic activities of Torasemide.
ToloxatoneToloxatone may increase the hypotensive activities of Torasemide.
TopiramateTorasemide may increase the hypokalemic activities of Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.
TrandolaprilTorasemide may increase the hypotensive activities of Trandolapril.
TranilastTranilast may decrease the diuretic activities of Torasemide.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Torasemide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Torasemide.
TravoprostTorasemide may increase the hypotensive activities of Travoprost.
TreprostinilTorasemide may increase the hypotensive activities of Treprostinil.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Torasemide.
TriamtereneThe risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.
TrichlormethiazideTorasemide may increase the hypotensive activities of Trichlormethiazide.
TrimazosinTorasemide may increase the hypotensive activities of Trimazosin.
TrimethaphanTorasemide may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Torasemide can be decreased when combined with Trimethoprim.
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Torasemide.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Torasemide.
UdenafilUdenafil may increase the antihypertensive activities of Torasemide.
UnoprostoneTorasemide may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the diuretic activities of Torasemide.
Valproic AcidThe metabolism of Torasemide can be decreased when combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Torasemide.
VardenafilVardenafil may increase the antihypertensive activities of Torasemide.
VerapamilThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.
VilanterolVilanterol may increase the hypokalemic activities of Torasemide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Torasemide.
VoriconazoleThe metabolism of Torasemide can be decreased when combined with Voriconazole.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Torasemide.
XylometazolineTorasemide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Torasemide.
ZafirlukastThe metabolism of Torasemide can be decreased when combined with Zafirlukast.
ZaltoprofenZaltoprofen may decrease the diuretic activities of Torasemide.
ZileutonZileuton may decrease the diuretic activities of Torasemide.
ZomepiracZomepirac may decrease the diuretic activities of Torasemide.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608 ]
  3. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. [PubMed:10406837 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23